Inclusion Criteria:

- Histologically or cytologically confirmed prostate cancer with a Gleason score
available or interpretable and meeting 1 of the following criteria:

- No prior chemotherapy and relatively minimal cancer spread

- Only one prior taxane-based chemotherapy for aggressive and/or symptomatic
disease

- Must have prostate cancer considered to be hormone refractory or androgen independent
by one or more of the following criteria (despite androgen deprivation and
anti-androgen withdrawal when applicable):

- Progression of unidimensionally measurable disease assessed within 28 days prior
to initial administration of drug

- Progression of evaluable but not measurable disease assessed within 28 days
prior to initial administration of drug for PSA evaluation and within 42 days
for imaging studies (e.g., bone scans)

- Patients must have nonmeasurable disease (e.g., nuclear medicine bone scans) and
non-target lesions (e.g., PSA level) assessed within 28 days prior to initial
administration of drug

- Measurable disease is not required but is allowed

- Must be surgically or medically castrated

- If the method of castration was luteinizing hormone-releasing hormone (LHRH)
agonists (e.g., leuprolide or goserelin), then the patient must be willing to
continue the use of LHRH agonists

- Serum testosterone must be at castrate levels (< 50 ng/dL) at least 3 months
prior to registration

- ECOG performance status 0-2

- WBC >= 3,000/uL

- Absolute neutrophil count >= 1,500/uL

- Platelets >= 100,000/uL

- Hemoglobin > 9 g/d

- Total bilirubin within normal institutional limits

- AST/ALT =< 2.5 x institutional upper limit of normal

- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min

- Must agree to use adequate contraception prior to study entry and for the duration of
study participation

- At least 3 weeks since the completion of chemotherapy and radiotherapy and the
patient must have recovered from the side effects of the therapy

- At least 28 days since prior non-steroidal anti-androgens (e.g., flutamide) (42 days
for bicalutamide or nilutamide) or hormonal treatment (e.g., ketoconazole) and
demonstrated progression of disease since the agents were suspended

- Concurrent bisphosphonate therapy is allowed

Exclusion Criteria:

- Known brain metastases

- History of allergic reactions attributed to compounds of similar chemical or
biological composition to AZD0530

- Patients with any of the following conditions that impair the ability to swallow
AZD0530 tablets

- Gastrointestinal tract disease resulting in an inability to take oral medication
or requiring IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would limit compliance with
study requirements

- Patients who have not recovered from adverse events due to agents administered more
than 4 weeks earlier

- Use of specifically prohibited CYP3A4-active agents or substances

- Prohibited drugs should be discontinued 7 days prior to the administration of
the first dose of AZD0530 and for 7 days following discontinuation of AZD0530

- Patients receiving any other investigational agents

- No investigational or commercial agents or therapies other than study drugs may be
administered with the intent to treat the patient's malignancy

- HIV-positive patients on combination antiretroviral therapy